43 results about "Gelsolin" patented technology

The invention relates to the use of gelsolin to treat infections and to monitor the treatment of infections. The invention also provides methods up-regulating interleukin expression and methods for down-regulating pro-inflammatory cytokine expression.

The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).

Provided are methods of using gelsolin and active fragments thereof to neutralize, treat or prevent the pathogenic effects of lipopolysaccharide (LPS) endotoxins released from gram-negative bacteria, including massive activation of inflammatory response in a patient and the resulting lethal septic shock. The provided gelsolin binds LPS from various bacteria with high affinity, decreasing circulating LPS and neutralizes its deleterious biological effects. Consequently, the provided gelsolin replacement therapy offers a method for the prevention of LPS-induced mortality in the patient.

The invention relates to the use of gelsolin to treat infections and to monitor the treatment of infections. The invention also provides methods up-regulating interleukin expression and methods for down-regulating pro-inflammatory cytokine expression.

The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.

The invention relates to the use of gelsolin to treat neurologic diseases (e.g., multiple sclerosis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of neurologic diseases.

The invention relates to the use of gelsolin to treat inflammatory diseases (e.g., rheumatoid arthritis) and to the use of gelsolin to diagnose, monitor, and evaluate therapies of inflammatory diseases (e.g., rheumatoid arthritis).

The invention relates to methods for determining the clinical outcome of a patient suffering ischemic stroke, for designing an individual therapy and for diagnosing a silent cerebrovascular disease comprising determining the levels of a marker selected from DPYSL2, gelsolin, CysA, or a combination thereof, the altered expression of which in relation to a reference value allows determining the clinical outcome of a patient suffering ischemic stroke, designing for designing an individual therapy or diagnosing a silent cerebrovascular disease. Furthermore, the invention relates to a kit comprising a reagent for detecting the level of a marker selected from DPYSL2, gelsolin, CysA, or a combination thereof and to the use of the said kit in the methods of the invention.

The present invention provides compositions and methods for selectively inhibiting the proliferation of stellate cells, which are important for the development of liver fibrosis upon liver injury. The invention describes conditioned media from immortalized hepatocytes as containing a death factor that induces apoptosis of activated liver stellate cells. This pro-apoptotic activity is shown to be associated with the peptide sequence of the actin depolymerizing molecule gelsolin and or fragments thereof. The apoptotic activity is increased upon incubation of immunoglobulins with the stellate death factor.

The invention relates to a method for determining the presence of renal damage in an individual and also to a method for detecting one or several proteins selected from the list comprising Reg3B, fetuin B, Ras-related GTP-binding protein A serine protease inhibitor A3L, subunit 1 of COP9, gamma subunit of ATP synthase, gelsolin, ribonuclease UK114, aminoacylase 1A, alpha-enolase, keratin 5, parvalbumin alpha, ribonuclease 4 or serine protease inhibitor A3K. The renal damage may be acute renal failure. Said renal pathologies may be caused by the administration of a nephrotoxic agent, wherein the nephrotoxic agent may be an aminoglycoside antibiotic such as gentamicin, or cisplatin. The invention also provides means to differentiate the renal damage or renal failure induced by gentamicin from that induced by cisplatin, through the biochemical analysis of the urinary level of Reg3B and / or gelsolin, or fragments thereof.

The invention relates to a method for expressing and purifying human cytoplasmic gelsolin (hcGSN). A recombinant expression vector pET-15b-hcGSN is constructed by designing a primer, IPTG inducible expression is used for obtaining N-end recombinant objective protein hcGSN with His labels, and recombinant protein hcGSN with high purity can be obtained through nickel ion affinity chromatography one-step purification. According to the method for expressing and purifying the hcGSN, cleavage sites of thrombin are further designed between the His labels and amino acid sequences of the hcGSN, and the His labels can be removed through the thrombin as needed. The method for producing and recombining the hcGSN is provided, massive soluble expression of the hcGSN in Escherichia coli is achieved, and the recombinant hcGSN with high purity can be efficiently, easily, conveniently and stably obtained through nickel ion affinity chromatography purification. The recombinant protein provides a material basis for related scientific researches and is possibly applied to prevention and treatment of diseases such as tumors and Alzheimer diseases in future.

The invention provides application of urine gelsolin (GSN) and polypeptide fragments of the urine gelsolin (GSN) in lung adenocarcinoma, and in particular relates to application of the urine gelsolin(GSN) and the polypeptide fragments of the urine gelsolin (GSN) in preparation of a preparation for detecting and auxiliary diagnosis of the lung adenocarcinoma. Researches confirm that compared witha normal control and a lung adenocarcinoma patient group, the urine gelsolin (GSN) is expressed in a low level in urine of a lung adenocarcinoma patient, and can be used for detection and auxiliary diagnosis of the lung adenocarcinoma. The advantages of non-invasive acquisition, large-scale repeated sampling, and convenient preservation of a urine specimen are played, and the urine specimen is used to detect the urine gelsolin (GSN) and the polypeptide fragments of the urine gelsolin (GSN).

The invention relates to application of miRNA in regulating and controlling expression levels of Gelsolin and application in antiplatelet treatment, and miRNA is miR-124. The invention further relatesto a method for screening reagents for regulating miRNA in blood platelet to screen potential antiplatelet treatment medicines. Screening tests show that ligustrazine, panax notoginseng saponins andaspirin can adjust the level of miR-124 in blood platelet cells, and thus functions are brought into play in antiplatelet treatment.

The invention belongs to the field of nanoparticle preparation in the biochemical technique, and particularly relates to a gelsolin inclusion and nano-crystallization method and a suspension. According to the implementation scheme, in parts by weight, under the normal temperature condition, gelsolin and hydroxypropyl-beta-cyclodextrin are added into a mortar in a proportion of 1:10, and a small amount of purified water is added for grinding for 4h; and then, a mixture of the gelsolin and hydroxypropyl-beta-cyclodextrin is filtered and freeze-dried to obtain a cyclodextrin / gelsolin inclusion complex. The inclusion complex is nano-crystallized to obtain the nanosuspension of a gelsolin-cyclodextrin inclusion complex. The method of the invention does not use an organic solvent or toxic cross-linking agent, has simple operation, a good inclusion effect and high repeatability, and is safe and reliable.

The invention provides diagnostic and therapeutic methods for neoplastic disease patients with neoplasms of, for example, the breast, skin, kidney, lung, pancreas, rectum and colon, prostate, bladder, epithelial, non-epithelial, lymphomas, sarcomas, melanomas, and the like, wherein the method comprises determining the level of expression o caveolin-1, caveolin-2, vimentin, calponin2, tropomyosin, gelsolin, prolyl 4-hydroxylase alpha, EF-I-delta, or M2-isoform of pyruvate kinase in stromal cells adjacent to the neoplasm.

The present invention relates to a method for screening a risk group of a hematologic disease and a method for analyzing the prognosis of a hematologic disease based on the measurement of the level of gelsolin mRNA in buffy coat of peripheral blood or a bone marrow aspirate. The use of the present invention enables the screening of a risk group of a hematologic disease and the analysis of prognosis of a patient with a hematologic disease in an easy and accurate manner.

Proteopathies cover a wide spectrum of afflictions, including neurodegenerative diseases (e.g., Alzheimer's, Parkinson's, polyglutamine diseasessuch as Huntingtin in Huntington's disease, prion diseases); amyloidosis of other non-nervous system proteins such as 1-antitrypsin, immunoglobulin light and heavy chains, lactadherin, apolipoprotein, gelsolin, lysozyme, fibrinogen, atrial natriuretic factor, keratin, lactoferrin and beta-2 microglobulin, among others); sickle cell disease; cataracts; cystic fibrosis; retinitis pigmentosa; and nephrogenic diabetes insipidus.Surprisingly, the administration of a sulfatase inhibitor is suitableto treat and / or prevent the proteotoxicity commonly associated with proteopathies. The present invention, therefore, provides compositions comprising sulfataseinhibitors for the treatment of proteopathies.

The invention relates to novel application of a gelsolin detection substance, in particular to application of the gelsolin detection substance in preparation of a reagent for uterine cancer disease risk assessment or prognosis effect assessment. The gelsolin detection substance is made into a detection reagent; the level of gelsolin in blood of a subject is detected, and then the level is compared with a preset value, so the risk of the subject suffering from the uterine cancer is obtained, or the prognosis effect of a patient suffering from the uterine cancer is evaluated; and experiments show that the gelsolin level in a specific range is closely related to the occurrence or poor prognosis of the uterine cancer.

The invention provides a cyclodextrin soluble gelsolin generation device and method and an atomization system. Airflow generated by an air compressor sequentially passes through a condenser and a second filter and enters an atomizer, and the atomizer atomizes cyclodextrin soluble gelsolin through compressed air. According to the invention, the function and effect of gelsolin are utilized, a cyclodextrin water-soluble gelsolin inclusion compound is prepared, the cyclodextrin water-soluble gelsolin inclusion compound is atomized and inhaled into a certain body cavity or a human body through an atomization device for generating clean compressed air, and the inclusion compound can release the gelsolin in the human body after entering the human body.

The present invention relates to the application of miRNA in regulating the expression level of Gelsolin and its application in antiplatelet therapy, and the miRNA is miR‑124. It also relates to a method for screening potential anti-platelet therapeutic drugs by screening agents that regulate the above-mentioned miRNA in platelets. Screening experiments showed that ligustrazine, panax notoginseng saponins and aspirin could regulate the level of miR‑124 in platelet cells, thus playing a role in antiplatelet therapy.

The present invention relates to novel DNA aptamers capable of binding gelsolin tightly and specifically. The invention further relates to the use of these aptamers to estimate the gelsolin levels in a given sample and purify bulk quantities of tagless gelsolin and its variants. The present invention thus eliminates the use of different animals / their tissues to produce gelsolin binding proteins, which are much more expensive and socially unacceptable methods as opposed to the synthesis of a DNA molecule by in vitro PCR. Using this strategy, bulk production of the gelsolin binding matrix can be carried out at much lower cost. Also, the aptamers can be used to block binding of gelsolin to its binding partners for diagnostic and / or therapeutic applications.

A method of treatment for treating, at least partly preventing, inhibiting or reducing tissue deterioration, injury or damage due to a periodontal disease or disease of oral mucosa, or for restoring tissue adversely affected by the disease, in a subject, and / or for downregulating NF-kappaB or suppressing NF-kappaB mediated action in a body, organ, tissue or cell, includes administering to a subject, body, organ, tissue or cell an effective amount of a composition including a peptide agent including at least one of Thymosin beta 4 (Tβ4), an isoform of Tβ4, an N-terminal fragment of Tβ4, a C-terminal fragment of Tβ4, Tβ4 sulfoxide, an LKKTET peptide or conservative variant thereof, an LKKTNT peptide or conservative variant thereof, a KLKKTET peptide or conservative variant thereof, an LKKTETQ peptide or conservative variant thereof, Tβ4ala, Tβ9, Tβ10, Tβ11, Tβ12, Tβ13, Tβ14, Tβ15, gelsolin, vitamin D binding protein (DBP), profilin, cofilin, depactin, DnaseI, vilin, fragmin, severin, capping protein, β-actinin, acumentin, an actin-sequestering peptide, an actin binding peptide, an actin-mobilizing peptide, an actin polymerization-modulating peptide, or a stimulating agent that stimulates production of an effective amount of the peptide agent in the subject, body, organ, tissue or cell.

The invention discloses application of a group of serum differential proteins in preparation of a reagent for detecting toxoplasma gondii infection of pigs. The serum differential proteins are one ora combination of more than one of fragments of toxoplasma gondii surface membrane proteins, HF proteins, vacuolar proteins, gelsolin and apolipoprotein CI. Whether the serum differential protein exists in serum or not is detected through an iTRAQ technology, and the concentration variation of the differential protein is detected and verified in combination with an MRM technology. The invention also discloses a detection kit for identifying toxoplasma gondii infection of pigs. The detection kit comprises an antibody for detecting the serum differential protein, a phosphate buffer solution and an ELISA 96-well plate. Whether pigs are infected with toxoplasma gondii or not can be rapidly and accurately identified, and the serum differential protein provided by the invention has the characteristics of objectivity, specificity and accuracy when used as a toxoplasmosis detection marker, and has a great market prospect.

The invention provides a fungal recombinant strain of high-yield oxalic acid. The fungal recombinant strain has a preservation number of CGMCC NO.9451 and a latin name as Beauveriabassiana, wherein the fungal recombinant strain is beauveria bassiana. The invention further provides a construction method of the fungal recombinant strain. The construction method comprises the following steps: utilizing entomopathogenic fungus beauveria bassiana as a research material, utilizing a gene knockout technology to damage a fungal Gelsolin gene to obtain an oxalic acid high-yield strain. The recombinant strain construction idea and the recombinant strain adopted in the invention provide relatively efficient and environment-friendly technical method for improving oxalic acid production.

A method for predicting the degree of weight loss in a female subject attainable by applying one or more dietary interventions to a subject, said method comprising; determining the level of one or more biomarkers in one or more samples obtained from the subject, wherein the biomarkers are selected from gelsolin, apolipoprotein B-100, plasma kallikrein, protein Z- dependent protease inhibitor and plasma serine protease inhibitor.

Provided are in vivo and in vitro methods for identifying or detecting a synapse which has been activated, or assessing the level of activation of a synapse, which method comprises: (i) determining the presence and\or amount, in a morphologically specialised postsynaptic site in the synapse (e.g. a dendritic spine), of a detectable cellular component associated with the activation (which is a ‘tag’ or ‘marker’ for the activation e.g. an actin-cytoskeleton interacting protein such as profilin II or gelsolin), and (ii) correlating the result of the determination with synaptic activation. Such assays can be useful in identifying processes involved in LTP, and also more generally in identifying modulators of synaptic activation or transmission, and hence cognitive function.